THE SOUTH AFRICAN
DEPRESSION AND ANXIETY
GROUP

facebooktwitter

IN THE WORKPLACE

New Research on Depression in the Workplace.

For more information please click here

business

SADAG NEWSLETTER

To subscribe to SADAG's newsletter, click here

JOURNAL

Mental Health Matters Journal for Psychiatrists & GP's

MHM September 207x300

Click here for more info on articles & how to subscribe

SPEAKING BOOKS

suicide book

Literacy is a luxury that many of us take for granted.  We depend on written communication for information, guidance, and access to heath care information That is why SADAG created SPEAKING BOOKS and revolutionized the way information is delivered to low literacy communities. It's exactly what it sounds like.a book that talks to the reader in his or her local  language, delivering critical information in an interactive, and educational way.

The customizable 16-page book, accompanied by local celebrity audio recordings, ensures that vital health and social messages can be seen, heard, read and understood..

We started with books on Teen Suicide prevention , HIV, AIDS and Depression, Understanding Mental Health and have developed over 30 titles, such as TB, Malaria, Polio, Vaccines for over 30 countries.

depression book

July 5, 2004 10:22:05 AM PDT , Reuters
Treatment with the antidepressant Cilexa significantly reduces symptoms of major depression in children and adolescents, researchers report.

Dr. Karen Dineen Wagner of the University of Texas Medical Branch, Galveston, and colleagues note in the American Journal of Psychiatry that previous open-label trials have indicated that Cilexa (also known technically as citalopram) was safe and effective in young patients.

To investigate further, the researchers conducted an 8-week long double-blind study of 174 patients, ranging in age from 12 to 17, with major depressive disorder.

They were randomly assigned to treatment with citalopram or an inactive placebo. Patients in the citalopram group showed a significantly greater reduction in average scores on the Children's Depression Rating Scale than did those in the placebo group.

Differences between the citalopram and placebo groups were seen after one week, and continued until the end of the study. At that point, the 36 percent response rate among participants given citalopram was significantly greater than the 24 percent seen in those given a placebo.

The rate of adverse events was similar between the groups, and none was serious, Wagner's team found.

These findings, the researchers conclude, "Further support the use of citalopram in children and adolescents suffering from depression."

SOURCE: American Journal of Psychiatry, June 2004.

 

Our Sponsors

Our Partners